The involvement of adenosine receptors in the effect of dizocilpine on mice in the elevated plus-maze

被引:12
|
作者
Fraser, CM [1 ]
Fisher, A [1 ]
Cooke, MJ [1 ]
Thompson, ID [1 ]
Stone, TW [1 ]
机构
[1] Univ Glasgow, Div Neurosci & Biomed Syst, Glasgow G12 8QQ, Lanark, Scotland
关键词
purines; adenosine; dizocilpine; MK-801; glutamate; NMDA; N-methyl-D-aspartate; anxiety; plus-maze;
D O I
10.1016/S0924-977X(97)00032-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
It has been claimed that blockade of receptors for N-methyl-D-aspartate (NMDA) can enhance adenosine receptor function on single neurones. Previous work has also indicated that the NMDA channel blocker dizocilpine, and the A(1) selective agonist N6-cyclopentyladenosine (CPA) both had anxiolytic profiles in the elevated plus-maze. The anxiolytic effect of dizocilpine was accompanied by an increase in locomotor activity. In the present study, the elevated plus-maze has been used to determine whether dizocilpine's effects on behaviour are mediated through activation of adenosine receptors. When co-administered with dizocilpine (0.05 mg/kg), CPA (0.05 mg/kg) reduced the anxiolytic and locomotor effects of dizocilpine. The A(1) selective antagonist 1,3-dipropyl-8-cyclopentylxanthine (CPX, 0.05 mg/kg) had no effect when administered alone. When co-administered with dizocilpine, CPX reversed the anxiolytic and increased locomotor effects induced by dizocilpine. The A(2) receptor selective agonist N6-[2-(3,5-dimethoxyphenyl)-2(2-methylphenyl)-ethyladenosine (DPMA) (1 mg/kg) reversed both the anxiolytic effect and the increased locomotion induced by dizocilpine, while the A(2) selective antagonist 3,7-dimethyl-1-propargylxanthine (DMPX) (1 mg/kg) did not. It is concluded that at least part of the anxiolytic and locomotor stimulant properties of dizocilpine may be explained by the release of endogenous adenosine acting at A1, but not A2 receptors. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:267 / 273
页数:7
相关论文
共 50 条
  • [31] ELEVATED PLUS-MAZE AND HOLE-BOARD EXPLORATION IN LURCHER MUTANT MICE
    MONNIER, C
    LALONDE, R
    BRAIN RESEARCH, 1995, 702 (1-2) : 169 - 172
  • [32] Study the Effect of Endocannabinoid System on Rat Behavior in Elevated Plus-Maze
    Komaki, Alireza
    Hashemi-Firouzi, Nasrin
    Shojaie, Shiva
    Souri, Zobin
    Heidari, Somayeh
    Shahidi, Siamak
    BASIC AND CLINICAL NEUROSCIENCE, 2015, 6 (03) : 147 - 153
  • [33] Effect of predatory stress on sucrose intake and behavior on the plus-maze in male mice
    Calvo-Torrent, A
    Brain, PF
    Martinez, M
    PHYSIOLOGY & BEHAVIOR, 1999, 67 (02) : 189 - 196
  • [34] Effect of the bone marrow cell transplantation on elevated plus-maze performance in hippocampal-injured mice
    da Cruz e Alves-de-Moraes, Luis Bruno
    Ribeiro-Paes, Joao Tadeu
    Longo, Beatriz Monteiro
    Ferrazoli, Eneas Galdini
    Carneiro Spera de Andrade, Telma Goncalves
    BEHAVIOURAL BRAIN RESEARCH, 2013, 248 : 32 - 40
  • [35] Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice
    Johnson, NJT
    Rodgers, RJ
    PSYCHOPHARMACOLOGY, 1996, 124 (04) : 355 - 364
  • [36] Effects of apomorphine on rat behavior in the elevated plus-maze
    Garcia, AMB
    Martinez, R
    Brandao, ML
    Morato, S
    PHYSIOLOGY & BEHAVIOR, 2005, 85 (04) : 440 - 447
  • [37] Effects of acute administration of bupropion on behavior in the elevated plus-maze test by NMRI mice
    Carrasco, MC
    Vicens, P
    Vidal, J
    Redolat, R
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (07) : 1135 - 1141
  • [38] UTILITY OF AN ELEVATED PLUS-MAZE FOR DISSOCIATION OF AMNESIC AND BEHAVIORAL-EFFECTS OF DRUGS IN MICE
    ITOH, J
    NABESHIMA, T
    KAMEYAMA, T
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 194 (01) : 71 - 76
  • [39] Oxiracetam prevents the MK-801 induced amnesia for the elevated plus-maze in mice
    Hlinák, Z
    Krejcí, I
    BEHAVIOURAL BRAIN RESEARCH, 2000, 117 (1-2) : 147 - 151
  • [40] INDOMETHACIN DOES NOT ANTAGONIZE THE ANXIOLYTIC ACTION OF ETHANOL IN THE ELEVATED PLUS-MAZE
    HALE, RL
    JOHNSTON, AL
    BECKER, HC
    PSYCHOPHARMACOLOGY, 1990, 101 (02) : 203 - 207